Diversified Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Diversified Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,548	Closed	-$616K	–	1050
2025 Q4	$616K	Sell	1,548 -22	-1%	-$9.74K	0.01%	605
2025 Q3	$716K	Buy	1,570 +472	+43%	+$192K	0.01%	506
2025 Q2	$358K	Sell	1,098 -384	-26%	-$106K	0.01%	698
2025 Q1	$400K	Sell	1,482 -999	-40%	-$257K	0.01%	639
2024 Q4	$584K	Sell	2,481 -749	-23%	-$197K	0.01%	549
2024 Q3	$888K	Sell	3,230 -1,748	-35%	-$455K	0.02%	414
2024 Q2	$1.21M	Buy	+4,978	New	+$786K	0.03%	284
2014 Q2	$243K	Buy	+3,840	New	+$228K	0.02%	502

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diversified Trust's ALNY Position: Q1 2026 in Review

Diversified Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,548 shares — an estimated $616K sold.

Diversified Trust first reported a position in ALNY in Q2 2014 and held it in 8 quarters. The position peaked at $1.21M in Q2 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Diversified Trust reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Diversified Trust sold 1,548 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $616K.
Diversified Trust first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Diversified Trust's Alnylam Pharmaceuticals position peaked at $1.21M in Q2 2024.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Diversified Trust's 13F filing for Q1 2026, filed 16 Apr 2026.